Skip to main content
Erschienen in: Wiener klinische Wochenschrift 9-10/2012

01.05.2012 | original article

Heparin-induced effects of prothrombin complex concentrates in thromboelastometry

verfasst von: Ass.-Prof. Gisela Scharbert, MD, Ulrich Thaler, MD, Christoph Weilnböck, MD, Léonore Wetzel, MD, Sibylle Kozek-Langenecker, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 9-10/2012

Einloggen, um Zugang zu erhalten

Summary

Background

Prothrombin complex concentrates (PCC) are currently used to treat congenital or acquired coagulation factor deficiency. In case of serious bleeding caused by new oral anticoagulant agents, reversing treatment with PCC is under debate. PCC preparations mostly contain heparin to prevent thromboembolic events. In factor VIII and IX deficient plasma, Takeyama et al. observed in vitro a heparin effect at appropriate concentrations of PCCs. The aim of the present experiment was to investigate the heparin effect of four factor-PCC at clinically relevant concentrations in whole blood. In an in vitro experiment, we compared the PCC preparation used in the experiments of Takeyama with a high heparin content to a new heparin-free PCC preparation.

Method

After ethics committee approval and written informed consent, the citrated whole blood was obtained from ten healthy volunteers. We tested heparin-containing Prothromplex® and heparin-free Cofact® at concentrations of 0.31, 0.63, and 1.25 IU/ml. Protamine was added to another set of samples (1:1 heparin:protamine). We used the NATEM test in the rotational thromboelastometer ROTEM®.

Results

In the heparin PCC preparation, we observed a significant (p < 0.001) concentration-dependent prolongation in CT and CFT, even at the lowest concentration. MCF was also significantly reduced. The heparin effect was reversible by protamine. The heparin-free PCC did not affect the onset of coagulation. The interpretation of the alpha-angle showed no increased thrombus formation in heparin-free PCC preparation.

Conclusion

Our results extend the report of Takeyama et al. At clinically relevant PCC concentrations, the heparin effect was significant in thromboelastometry. The heparin content of PCCs should be considered in clinical routine.
Literatur
1.
Zurück zum Zitat Hellstern P, Halbmayer WM, Kohler M, Seitz R, Muller-Berghaus G. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res. 1999;95:3–6.CrossRef Hellstern P, Halbmayer WM, Kohler M, Seitz R, Muller-Berghaus G. Prothrombin complex concentrates: indications, contraindications, and risks: a task force summary. Thromb Res. 1999;95:3–6.CrossRef
2.
Zurück zum Zitat Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4:967–70.PubMedCrossRef Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost. 2006;4:967–70.PubMedCrossRef
3.
Zurück zum Zitat Takeyama M, Sakurai Y, Shima M, Matsumoto T, Nogami K, Tanaka I, et al. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis. Blood Coagul Fibrinolysis. 2007;18:1–7.PubMedCrossRef Takeyama M, Sakurai Y, Shima M, Matsumoto T, Nogami K, Tanaka I, et al. Heparin-induced inhibitory effects of a prothrombin complex concentrate on global tests of haemostasis. Blood Coagul Fibrinolysis. 2007;18:1–7.PubMedCrossRef
4.
Zurück zum Zitat Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622–31.PubMedCrossRef Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost. 2008;6:622–31.PubMedCrossRef
5.
Zurück zum Zitat Lavenne-Pardonge E, Itegwa MA, Kalaai M, Klinkenberg G, Loncke JL, Pelgrims K, et al. Emergency reversal of oral anticoagulation through PPSB-SD: the fastest procedure in Belgium. Acta Anaesthesiol Belg. 2006;57:121–5.PubMed Lavenne-Pardonge E, Itegwa MA, Kalaai M, Klinkenberg G, Loncke JL, Pelgrims K, et al. Emergency reversal of oral anticoagulation through PPSB-SD: the fastest procedure in Belgium. Acta Anaesthesiol Belg. 2006;57:121–5.PubMed
6.
Zurück zum Zitat Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol. 2007;73:401–15.PubMed Kozek-Langenecker S. Management of massive operative blood loss. Minerva Anestesiol. 2007;73:401–15.PubMed
7.
Zurück zum Zitat Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract. 2008;62:1614–22.PubMedCrossRef Kalina U, Bickhard H, Schulte S. Biochemical comparison of seven commercially available prothrombin complex concentrates. Int J Clin Pract. 2008;62:1614–22.PubMedCrossRef
8.
Zurück zum Zitat Nielsen VG. The detection of changes in heparin activity in the rabbit: a comparison of anti-Xa activity, thromboelastography, activated partial thromboplastin time, and activated coagulation time. Anesth analg. 2002;95(6):1503–6.PubMedCrossRef Nielsen VG. The detection of changes in heparin activity in the rabbit: a comparison of anti-Xa activity, thromboelastography, activated partial thromboplastin time, and activated coagulation time. Anesth analg. 2002;95(6):1503–6.PubMedCrossRef
9.
Zurück zum Zitat Klein SM, Slaughter TF, Vail PT, Ginsberg B, El-Moalem HE, Alexander R, et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesth analg. 2000;91(5):1091–5.PubMed Klein SM, Slaughter TF, Vail PT, Ginsberg B, El-Moalem HE, Alexander R, et al. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations. Anesth analg. 2000;91(5):1091–5.PubMed
10.
Zurück zum Zitat Zmuda K, Neofotistos D, Ts’ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J clin pathol. 2000;113(5):725–31.PubMedCrossRef Zmuda K, Neofotistos D, Ts’ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J clin pathol. 2000;113(5):725–31.PubMedCrossRef
11.
Zurück zum Zitat Pfanner G, Koscielny J, Pernerstorfer T, Gutl M, Perger P, Fries D, et al. Preoperative evaluation of the bleeding history. Recommendations of the working group on perioperative coagulation of the Austrian Society for Anaesthesia, Resuscitation and Intensive Care. Anaesthesist. 2007;56:604–11.PubMedCrossRef Pfanner G, Koscielny J, Pernerstorfer T, Gutl M, Perger P, Fries D, et al. Preoperative evaluation of the bleeding history. Recommendations of the working group on perioperative coagulation of the Austrian Society for Anaesthesia, Resuscitation and Intensive Care. Anaesthesist. 2007;56:604–11.PubMedCrossRef
12.
Zurück zum Zitat Schochl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010;14:R55.PubMedCrossRef Schochl H, Nienaber U, Hofer G, Voelckel W, Jambor C, Scharbert G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. Crit Care. 2010;14:R55.PubMedCrossRef
13.
Zurück zum Zitat Schochl H, Solomon C, Schulz A, Voelckel W, Hanke A, Van Griensven M,et al. Thromboelastometry (Tem) findings in disseminated intravascular coagulation in a pig model of endotoxinemia. Mol Med. 2011;17(3–4):266–72.PubMed Schochl H, Solomon C, Schulz A, Voelckel W, Hanke A, Van Griensven M,et al. Thromboelastometry (Tem) findings in disseminated intravascular coagulation in a pig model of endotoxinemia. Mol Med. 2011;17(3–4):266–72.PubMed
14.
Zurück zum Zitat Bowbrick VA, Mikhailidis DP, Stansby G. The use of citrated whole blood in thromboelastography. Anesth Analg. 2000;90:1086–8.PubMedCrossRef Bowbrick VA, Mikhailidis DP, Stansby G. The use of citrated whole blood in thromboelastography. Anesth Analg. 2000;90:1086–8.PubMedCrossRef
15.
16.
Zurück zum Zitat Lang T, Bauters A, Braun SL, Potzsch B, von Pape KW, Kolde HJ, et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis. 2005;16:301–10.PubMedCrossRef Lang T, Bauters A, Braun SL, Potzsch B, von Pape KW, Kolde HJ, et al. Multi-centre investigation on reference ranges for ROTEM thromboelastometry. Blood Coagul Fibrinolysis. 2005;16:301–10.PubMedCrossRef
17.
Zurück zum Zitat van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118:313–20.PubMedCrossRef van Aart L, Eijkhout HW, Kamphuis JS, Dam M, Schattenkerk ME, Schouten TJ, et al. Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: an open, prospective randomized controlled trial. Thromb Res. 2006;118:313–20.PubMedCrossRef
18.
Zurück zum Zitat Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B,et al. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med. 1999;25:1105–10.PubMedCrossRef Staudinger T, Frass M, Rintelen C, Quehenberger P, Wagner O, Stoiser B,et al. Influence of prothrombin complex concentrates on plasma coagulation in critically ill patients. Intensive Care Med. 1999;25:1105–10.PubMedCrossRef
19.
Zurück zum Zitat Mannucci PM, Franchi F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet. 1976;2:542–5.PubMedCrossRef Mannucci PM, Franchi F, Dioguardi N. Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates. Lancet. 1976;2:542–5.PubMedCrossRef
20.
Zurück zum Zitat Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465–70.PubMedCrossRef Huttner HB, Schellinger PD, Hartmann M, Kohrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke. 2006;37:1465–70.PubMedCrossRef
21.
Zurück zum Zitat Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:340–80.CrossRef Warkentin TE, Greinacher A, Koster A, Lincoff AM. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133:340–80.CrossRef
22.
Zurück zum Zitat Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313–8.PubMedCrossRef Buller H, Deitchman D, Prins M, Segers A. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313–8.PubMedCrossRef
23.
Zurück zum Zitat Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood. 2008;112:2242–7.PubMedCrossRef Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT dose-ranging study. Blood. 2008;112:2242–7.PubMedCrossRef
24.
Zurück zum Zitat Eriksson BI, Smith H, Yasothan U, Kirkpatrick P. Dabigatran etexilate. Nat Rev Drug Discov. 2008;7:557–8.PubMedCrossRef Eriksson BI, Smith H, Yasothan U, Kirkpatrick P. Dabigatran etexilate. Nat Rev Drug Discov. 2008;7:557–8.PubMedCrossRef
25.
Zurück zum Zitat Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–56.PubMedCrossRef Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949–56.PubMedCrossRef
26.
Zurück zum Zitat Levi MM, Eerenberg E, Lowenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med. 2010;68:68–76.PubMed Levi MM, Eerenberg E, Lowenberg E, Kamphuisen PW. Bleeding in patients using new anticoagulants or antiplatelet agents: risk factors and management. Neth J Med. 2010;68:68–76.PubMed
27.
Zurück zum Zitat McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100:1576–83.PubMedCrossRef McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg. 2005;100:1576–83.PubMedCrossRef
28.
Zurück zum Zitat Mittermayr M, Margreiter J, Velik-Salchner C, Klingler A, Streif W, Fries D, et al. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth. 2005;95:310–6.PubMedCrossRef Mittermayr M, Margreiter J, Velik-Salchner C, Klingler A, Streif W, Fries D, et al. Effects of protamine and heparin can be detected and easily differentiated by modified thrombelastography (Rotem): an in vitro study. Br J Anaesth. 2005;95:310–6.PubMedCrossRef
Metadaten
Titel
Heparin-induced effects of prothrombin complex concentrates in thromboelastometry
verfasst von
Ass.-Prof. Gisela Scharbert, MD
Ulrich Thaler, MD
Christoph Weilnböck, MD
Léonore Wetzel, MD
Sibylle Kozek-Langenecker, MD
Publikationsdatum
01.05.2012
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 9-10/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-012-0171-8

Weitere Artikel der Ausgabe 9-10/2012

Wiener klinische Wochenschrift 9-10/2012 Zur Ausgabe

mitteilungen der gesellschaft

Billrothaus